Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18179110 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA) | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17761641 | COMPOSITIONS AND METHODS FOR DELIVERING CARGO TO A TARGET CELL | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17632322 | METHODS OF BULK DROPLET VITRIFICATION | Non-Final OA | The General Hospital Corporation |
| 17997108 | COMPOSITIONS AND METHODS FOR REDUCING NUCLEASE EXPRESSION AND OFF-TARGET ACTIVITY USING A PROMOTER WITH LOW TRANSCRIPTIONAL ACTIVITY | Final Rejection | The Trustees of the University of Pennsylvania |
| 17870029 | MOLECULES AND METHODS FOR INCREASED TRANSLATION | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17773467 | METHOD FOR PRODUCING T CELLS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | Non-Final OA | UCL BUSINESS LTD |
| 18268597 | Medium for the in vitro transportation and storage of cells | Non-Final OA | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy